Reduced overall survival in TP53-mutated ccus is driven by prior cytotoxic exposure and cytopenia rather than leukemic progression
Steven Tessier(Mayo Clinic in Arizona), Mithun Vinod Shah(Mayo Clinic in Arizona), Aref Al‐Kali(Mayo Clinic), Kebede Begna(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic), Ayalew Tefferi(Mayo Clinic), Yazan Khair Eldien Jabban(Rochester Institute of Technology), Cecilia Arana Yi(Mayo Clinic Hospital), Hemant S. Murthy(University of Florida), Laura Ongie(Mayo Clinic), James M. Foran(Memorial Sloan Kettering Cancer Center), Devendra Hiwase(Australasian Leukaemia and Lymphoma Group), Hassan B. Alkhateeb(Mayo Clinic), Yael Kusne(WinnMed), Mrinal M. Patnaik(Mayo Clinic), Talha Badar(Mayo Clinic in Florida), William J. Hogan(Mayo Clinic), Naseema Gangat(Mayo Clinic in Arizona), Nathan Punwani(Mayo Clinic in Florida), Antoine N. Saliba(Mayo Clinic in Arizona)
Cited by 0
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k